Amazon Web Services (AWS) has launched a new artificial intelligence platform, Amazon Bio Discovery, enabling researchers to generate and assess potential drug candidates using natural language prompts. This single workflow requires no coding, creating a continuous feedback loop for scientists.
"AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise," stated Rajiv Chopra, Vice President at AWS. "This combination of cutting-edge AI and the robust, secure infrastructure allow scientists to accelerate antibody discovery in ways that weren’t possible before."
The platform also allows scientists to train AI models using their own private experimental data, without building dedicated machine learning infrastructure.
Memorial Sloan Kettering Cancer Center (MSK) is an early adopter, using the platform to generate approximately 300,000 potential antibody candidates, reducing a typical year-long timeline to just a few weeks. "Patients come here with a clock. We need results sooner," said Nai-Kong Cheung, Chair of Pediatric Oncology at MSK.
Bayer, the Broad Institute, Fred Hutch Cancer Center, and Voyager Therapeutics are also among the early adopters.